Abstract:Abstract Background 80% of patients diagnosed with esophageal adenocarcinoma (EAC) die of disease. Current standard of care for EAC is systemic cytotoxic, platinum-based neoadjuvant chemotherapy followed by resection and additional rounds of chemotherapy. Locally advanced, resectable patients often fail to respond due to intrinsic and/or acquired chemoresistance. Traditional preclinical models fail to offer alternative salvage options. To our knowledge, this is the first high-fidelity dynamic 3D platform implemented to study esophageal function, pathophysiology, and drug effects. Methods Primary tissues obtained from EAC patients at diagnostic biopsy were propagated into patient-derived organoids (PDOs). The upper (mucosal) channel of the esophagus-chip was designated for PDO-derived epithelial cells, while the lower stromal channel was designated for matched fibroblasts. Autologous cell types were exposed to a physiologically relevant flow of nutrient media and microtissues were formed. Epithelial permeability was determined by cascade blue assay. Using this model, a clinically relevant chemotherapy protocol was administered to study patient-specific tumor response. To determine microtissue development and cellular fate in response to chemotherapy, level of several epithelial/mesenchymal biomarkers were evaluated. Results Study cohort consisted of both chemo-sensitive and -resistant EAC patients. Esophagus-chip models were developed with samples from patient-matched tumor and normal tissue. Chips recapitulated morphological and histological features of their parental tissues. Epithelial barrier integrity was established within 5 days on-chip. Scanning electron microscopy revealed the presence of pleomorphic cells and mature microvilli in EAC-chips. In vitro administration of docetaxel triplet chemotherapy demonstrated efficacy similar to that observed in the clinical setting when assessed directly or indirectly. Confocal imaging revealed treatment-associated differential expression of epithelial (CK7, CK19), and mesenchymal (vimentin) markers. Conclusion 3D-organoids conserve cellular heterogeneity of source patients, whereas esophagus-on-chip expand on this diversity by adding microphysiological relevance, stromal influence & flexible complexity. This high-fidelity biomimetic platform enables clinical mimicry and can predict patient-specific chemosensitivity within a clinically relevant timeframe. This esophagus-chip system is a promising potential replacement for both inefficient preclinical animal models and existing tumor-only avatars lacking stromal and microphysiological context.

Modeling Epithelial Homeostasis and Perturbation in Three-Dimensional Human Esophageal Organoids

Modeling epithelial homeostasis and perturbation in three-dimensional human esophageal organoids

Understanding the cellular origin and progression of esophageal cancer using esophageal organoids

Efficient Derivation of Basal Progenitor Cells from Human Pluripotent Stem Cells for Modeling Esophageal Development

3D Modeling of Esophageal Development Using Human PSC-Derived Basal Progenitors Reveals a Critical Role for Notch Signaling.

Establishment of a High-Resolution 3D Modeling System for Studying Pancreatic Epithelial Cell Biology in Vitro

An integrated transcriptomic cell atlas of human endoderm-derived organoids

Development and Characterization of a Three-Dimensional Organotypic In Vitro Oral Cancer Model with Four Co-Cultured Cell Types, Including Patient-Derived Cancer-Associated Fibroblasts

Esophageal squamous cell carcinoma model of 3D organotypic tissue culture system with genetic modification of epithelial growth factor receptor and p120‐catenin (1119.3)

Development and Application of a Functional Human Esophageal Mucosa Explant Platform to Eosinophilic Esophagitis

Establishment of a Novel Model for Anticancer Drug Resistance in Three-Dimensional Primary Culture of Tumor Microenvironment

3D Organoids: An Untapped Platform for Studying Host–Microbiome Interactions in Esophageal Cancers

Establishing mouse and human oral esophageal organoids to investigate the tumor immune response

268. DEVELOPMENT OF A NOVEL ESOPHAGUS-ON-A-CHIP MODEL: A HIGH-FIDELITY PLATFORM FOR DIRECTING PERSONALIZED THERAPY IN ESOPHAGEAL ADENOCARCINOMA

Protocol for the generation, characterization, and functional assays of organoid cultures from normal and cancer-prone human esophageal tissues

Intestinal organoids: A versatile platform for modeling gastrointestinal diseases and monitoring epigenetic alterations

Molecular and Functional Characterization of Human Intestinal Organoids and Monolayers for Modeling Epithelial Barrier

Long-Term Monolayer Cultivation Captures Homeostatic and Regenerative Features of Human Colonic Epithelial Cells

Generation of hiPSC-Derived Intestinal Organoids for Developmental and Disease Modelling Applications

Disease Modeling Using 3D Organoids Derived from Human Induced Pluripotent Stem Cells

Patient-Derived Tumor Organoid and Fibroblast Assembloid Models for interrogation of the tumor microenvironment in Esophageal Adenocarcinoma